COGNITION THERAPEUTICS INC CGTX
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances)
Chart by TradingView
2/9
Piotroski F — financial health
-12.85
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | — | -$23.5M | — | — | $34.3M |
| 2024 | — | -$34.0M | — | -$28.5M | $18.8M |
| 2023 | — | -$25.8M | — | -$16.2M | $24.5M |
| 2022 | — | -$21.4M | — | -$18.7M | $40.2M |
| 2021 | — | -$11.7M | — | -$3.7M | $51.3M |
| 2020 | — | -$7.8M | — | -$3.4M | -$68.2M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Khattar Jack A. | director | 2026-06-17 | Grant | 25,000 | — |
| Monia Brett P | director | 2026-06-17 | Grant | 25,000 | — |
| Wallace Peggy | director | 2026-06-17 | Grant | 25,000 | — |
| RICHSTONE ELLEN B | director | 2026-06-17 | Grant | 25,000 | — |
| Fletcher Aaron G.L. | director | 2026-06-17 | Grant | 25,000 | — |
| Doyle John Brendan | Chief Financial Officer | 2026-05-01 | Tax withheld | 8,567 | $1.28 |
| Doyle John Brendan | Chief Financial Officer | 2026-04-16 | Buy | 10,000 | $1.13 |
| Ricciardi Lisa | CEO & President | 2026-04-16 | Buy | 9,175 | $1.10 |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -12.85 (distress)
- Working capital / assets 0.704
- Retained earnings / assets -4.105
- EBIT / assets -0.988
- Equity / liabilities 2.427
Source: SEC EDGAR filings · CIK 0001455365 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.